4DMT reports encouraging Phase 2 PRISM interim outcomes for Intravitreal 4D-150 in diverse wet AMD patients, confirming positive safety and strong clinical efficacy.

Pluvicto, whose generic name is lutetium Lu 177 vipivotide tetraxetan, received FDA approval for its indicated use in adult patients with PSMA-positive mCRPC.

Bayer reveals promising primary results for NUBEQA® (darolutamide) from a Phase III study in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Nivolumab and relatlimab received FDA approval for the treatment of unresectable or metastatic melanoma on March 18, 2022.

Genentech Reports Promising Phase I Outcomes for Oral GLP-1 Receptor Agonist CT-996 in Obesity Treatment.

Ganaxolone, marketed under the brand name Ztalmy, is FDA approved for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD) in individuals aged 2 years and older.

Jul 23rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Pacritinib, with the generic name pacritinib [pak-RI-ti-nib], is approved by the FDA for the treatment of myelofibrosis in adults.

NexThera Co., Ltd. announced the submission of a Phase 1/2a Investigational New Drug application to the U.S. Food and Drug Administration for NT-101.

Ciltacabtagene autoleucel received FDA approval on February 28, 2022.

Celldex Therapeutics launches worldwide Phase 3 trial of Barzolvolimab for chronic spontaneous urticaria patients.

Mitapivat (Pyrukynd) was approved by the FDA on February 17, 2022.